NATCO, Alvogen file ANDA for Ibrutinib Tablets for the USA market

31 Jan 2019 Evaluate

Natco Pharma and Alvogen Pine Brook LLC, USA, have submitted Abbreviated New Drug Application (ANDA) containing a paragraph IV certification with the US Food and Drug Administration (USFDA) for generic version of Ibrutinib Tablets of 140mg, 280mg, 420mg and 560mg strength (proposed generic equivalents to Imbruvica Tablets).

ANDA may be eligible for 180 days of marketing exclusivity at the time of potential launch of the product under certain circumstances.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.


Natco Pharma Share Price

964.50 27.45 (2.93%)
20-Mar-2026 13:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1780.35
Dr. Reddys Lab 1305.25
Cipla 1259.40
Zydus Lifesciences 895.90
Lupin 2336.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×